EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma

Masaharu Shinkai, Tadataka Yabuta

Immunotherapy · 2023-12 · 15 (17) · 1435-1447

DOI: 10.2217/imt-2023-0079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunotherapy, online erschienen am 19.09.2023. Verfasst von Masaharu Shinkai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo, 140-8522, Japan. Hauptthemen laut MEDLINE: Thymic Stromal Lymphopoietin, Asthma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a common chronic respiratory disease in which epithelial cytokines and airway inflammation play critical pathophysiological roles. Thymic stromal lymphopoietin (TSLP), an epithelial cytokine, is central in the initiation and persistence of airway inflammation in asthma. Tezepelumab is a human immunoglobulin G2λ (IgG2λ) monoclonal antibody developed for treating moderate-to-severe asthma by specifically binding to TSLP and preventing its binding to the TSLP receptor on inflammatory cells. In this narrative review, we describe the results of clinical trials that evaluated the pharmacokinetics, pharmacodynamics, efficacy and safety of tezepelumab in patients with moderate-to-severe asthma. We also introduce the ongoing clinical trials in patients with asthma as well as future trials investigating the use of tezepelumab for other indications. Asthma is a long-term disease that causes inflammation in the cells of the lung. One of the cytokines (proteins) involved in asthma is called thymic stromal lymphopoietin (TSLP). This cytokine is produced by the airway epithelium, a layer of cells covering the respiratory tract in the lungs, where it activates inflammatory cells. Tezepelumab is a new drug that blocks the activity of TSLP in the lungs and helps reduce asthma symptoms, such as coughing and breathlessness. In this article, we describe the clinical trials that investigated how well tezepelumab works, as well as its safety, in people with moderate or severe asthma. We also describe the trials of tezepelumab that are now underway in people with asthma, allergies or other inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thymic Stromal LymphopoietinAsthmaHumansCytokinesAntibodies, MonoclonalInflammationAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Th2 cellasthmaclinical trialepithelial cytokineinflammationinnate lymphocytelung healthtezepelumabthymic stromal lymphopoietin

Substanzen

Thymic Stromal LymphopoietinCytokinesAntibodies, MonoclonaltezepelumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo, 140-8522, Japan.
  • Medical Department, AstraZeneca K.K., 3-1 Ofukacho, Kita-ku, Osaka, 530-0011, Japan.

Förderung

  • AstraZeneca K.K.

Zitieren

APA

Shinkai, M., & Yabuta, T. (2023). Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma. Immunotherapy, 15(17), 1435-1447. https://doi.org/10.2217/imt-2023-0079

Vancouver

Shinkai M, Yabuta T. Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma. Immunotherapy. 2023;15(17):1435-1447. doi:10.2217/imt-2023-0079

BibTeX
@article{Shinkai2023,
  author = {Shinkai, Masaharu and Yabuta, Tadataka},
  title = {Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma},
  journal = {Immunotherapy},
  year = {2023},
  volume = {15},
  number = {17},
  pages = {1435--1447},
  doi = {10.2217/imt-2023-0079}
}
Kostenlos starten →